Literature DB >> 21159885

Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

Carlo Sorrentino1, Piero Musiani, Paolo Pompa, Giuseppe Cipollone, Emma Di Carlo.   

Abstract

PURPOSE: The value of neoadjuvant hormone therapy (NHT) prior to radical prostatectomy as a means of restraining prostate cancer (PCa) and strengthening its immunotherapy is still uncertain. This article asks whether it subverts immunoregulatory pathways governing tumor microenvironments, and has an impact on patient outcome. EXPERIMENTAL
DESIGN: We microdissected epithelium and stroma from cancerous and normal prostate specimens from 126 prostatectomized patients, of whom 76 had received NHT, to detect cytokine/chemokine gene expression levels by real-time reverse transcriptase PCR. Confocal microscopy was used to identify cytokine/chemokine cell sources, and immunostainings to characterize lymphocyte subsets whose prognostic effects were assessed by Kaplan-Meier analyses.
RESULTS: NHT boosted the expression of IL-7 in the stroma and that of IFNγ-inducible protein-10/CXCL10 in the glandular epithelium of normal prostate tissue, and restored the CD8(+) lymphocyte depletion occurring in PCa, whereas it significantly increased the CD4(+) lymphocyte infiltrate. Lymphocytes, mostly with CD8(+) phenotype, expressed the T-cell intracellular antigen-1, granzyme-B, and perforin, typical of cytotoxic-effector T cells. NHT also induced thymus and activation-regulated chemokine/CCL17 production by monocytes/macrophages in the prostate and draining lymph nodes, and increased the number of their Forkhead box P3 (Foxp3)(+)CD25(+)CD127(-) T regulatory (Treg) cells. The χ(2) test disclosed the lack of association (P = 0.27) between NHT and the high intratumoral CD8(+)/Treg ratio indicative of a good prognosis.
CONCLUSIONS: Androgen withdrawal regulates cytokine/chemokine gene expression in normal prostate and lymphoid tissues, and this probably favors both CD8(+) and Treg infiltrates, leaves their intratumoral balance unchanged, and thus has no impact on disease-free survival. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159885     DOI: 10.1158/1078-0432.CCR-10-2804

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.

Authors:  Shuai Tang; Miranda L Moore; Jason M Grayson; Purnima Dubey
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

2.  T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.

Authors:  Matthew D Morse; Douglas G McNeel
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

3.  TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Authors:  Harsimar B Kaur; Jiayun Lu; Liana B Guedes; Laneisha Maldonado; Logan Reitz; John R Barber; Angelo M De Marzo; Scott A Tomlins; Karen S Sfanos; Mario Eisenberger; Edward M Schaeffer; Corinne E Joshu; Tamara L Lotan
Journal:  Hum Pathol       Date:  2019-03-06       Impact factor: 3.466

4.  Sex and age as determinants of rat T-cell phenotypic characteristics: influence of peripubertal gonadectomy.

Authors:  Nevena Arsenović-Ranin; Duško Kosec; Ivan Pilipović; Mirjana Nacka-Aleksić; Biljana Bufan; Zorica Stojić-Vukanić; Gordana Leposavić
Journal:  Mol Cell Biochem       Date:  2017-03-09       Impact factor: 3.396

Review 5.  Immunotherapy for the treatment of prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Philip W Kantoff
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

6.  Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor.

Authors:  Boyu Zhang; Oh-Joon Kwon; Gervaise Henry; Alicia Malewska; Xing Wei; Li Zhang; William Brinkley; Yiqun Zhang; Patricia D Castro; Mark Titus; Rui Chen; Mohammad Sayeeduddin; Ganesh V Raj; Ryan Mauck; Claus Roehrborn; Chad J Creighton; Douglas W Strand; Michael M Ittmann; Li Xin
Journal:  Mol Cell       Date:  2016-09-01       Impact factor: 17.970

Review 7.  Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Authors:  Tanya B Dorff; L Michael Glode
Journal:  Curr Opin Urol       Date:  2013-07       Impact factor: 2.309

8.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Authors:  Brian M Olson; Ewa Jankowska-Gan; Jordan T Becker; Dario A A Vignali; William J Burlingham; Douglas G McNeel
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

Review 9.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

Review 10.  The addition of chemotherapy in the definitive management of high risk prostate cancer.

Authors:  Matthew J Ferris; Yuan Liu; Jingning Ao; Jim Zhong; Mustafa Abugideiri; Theresa W Gillespie; Bradley C Carthon; Mehmet A Bilen; Omer Kucuk; Ashesh B Jani
Journal:  Urol Oncol       Date:  2018-10-09       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.